

Upcoming Medicaid Pharmacy Benefit Change

Neighborhood News – October 2023

Beginning October 15, 2023, Neighborhood Health Plan of Rhode Island's (Neighborhood) Medicaid Pharmacy Benefit will remove Humira from Neighborhood's Medicaid formulary. Instead, Neighborhood will **exclusively prefer the following adalimumab biosimilars:**

- Hadlima (adalimumab-bwwd)
- Adalimumab-adaz
- Adalimumab-fkjp

Also, effective October 15, all Medicaid adult members currently using Humira will need a new prescription for one of the preferred biosimilar products listed above. This is because existing authorizations for Humira will expire on that date.

Pediatric members who are already on branded Humira can continue their treatment with the same product. Pediatric members who are new to adalimumab therapy will be required to use a biosimilar therapy if indicated.

If a member has taken Humira in the past 180 days, they do NOT need a new authorization to transition to a biosimilar product. Reauthorizations are not required for biosimilar adalimumab products.

Please note, Hadlima, adalimumab-adaz, and adalimumab-fkjp were added to the Medicaid formulary on August 1, 2023. Providers may begin prescribing them immediately to facilitate the transition for members.